PURE’s SDC Antimicrobial is a Featured Listeria Solution in Food Safety Consortium Presentation by James Marsden, Ph.D.

Dr. Marsden Also Leads ‘Ask the Expert’ Discussion at the Summit

Attended by Food Safety Industry Experts and Government Officials

), creator of the patented silver dihydrogen citrate (SDC)
antimicrobial, today announced that the superior efficacy and safety of
its SDC-based technology was highlighted as a Listeria control
solution in a presentation made this week by James L. Marsden, Ph.D.,
Distinguished Professor – Food Safety and Security at Kansas State
University, at the Food Safety Consortium in Chicago.

The Food Safety Consortium conference is a leading summit meeting of
Food Safety and Quality Assurance industry experts and government
officials. The four-day conference drew hundreds of attendees comprised
of leading industry experts, and featured prominent speakers (including
the VP-Food Safety, Walmart; and the Deputy Commissioner for Foods, U.S.
FDA). Conference topics included Compliance (FSMA and GFSI), Food
Manufacturing Operations, Food Safety Supply Chain Management, Food Labs
and Foodservice & Retail Food Safety.

Dr. Marsden discussed the efficacy and safety of PURE’s SDC-based food
safety solution technology in his presentation titled ‘Identifying and
Controlling Listeria in Food Processing Facilities.’ An ‘Ask The
Expert’ discussion group session at the conference was also led by Dr.
Marsden. Dr. Marsden is the author of the December 1, 2014 White
‘Remediation of Listeria Contamination in a Wheeling,
Illinois Food Processing Facility’ which discussed how PURE® Hard
Surface (food contact surface disinfectant) was used to successfully
remediate Listeria in the contaminated plant, leading to the
FDA’s approval to re-open the plant for food production.

Dr. Marsden stated, “SDC’s residual kill properties provide continuous
decontamination and control, which is especially important on floors, in
drains and other harborage points where Listeria lives in every
plant. This clearly distinguishes SDC from other chemistries in use
today, and is the most important aspect of an effective Listeria
control program.”

R. Lambert
, Chief Executive Officer, said that, “We are proud that
our SDC food safety solution technology was selected for presentation
and discussion with this important and influential group of food safety
experts and officials. It is further validation that our superior
efficacy, environmentally friendly antimicrobial technology is a leading
solution for reducing the growing risk of foodborne illness outbreaks.

“Not only is SDC a superior solution for Listeria elimination, as
discussed at the conference, but application of SDC has also achieved
dramatic reductions in Salmonella, E. coli and Norovirus,”
continued Lambert.

“We look forward to greatly expanding SDC’s reach and ability to
mitigate foodborne illness when we receive FDA approvals for use of PURE
Control® in direct food contact applications. The FCN (food contact
notification) for raw
poultry processing
is anticipated later in December, and the FCN for fresh
processing is anticipated in January. With subsequent USDA
approval for raw poultry processing, we look forward to commercializing
PURE Control into these combined $650 million markets by the end of
calendar Q1 2016, and executing our plan to capture a significant share
of these growing markets,” concluded Lambert.

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused
on developing and commercializing our proprietary antimicrobial products
primarily in the food safety arena — providing solutions to the health
and environmental challenges of pathogen and hygienic control. Our
technology platform is based on patented stabilized ionic silver, and
our initial products contain silver dihydrogen citrate, or SDC. SDC is a
broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour
residual protection and formulates well with other compounds. As a
platform technology, SDC is distinguished from existing products in the
marketplace because of its superior efficacy, reduced toxicity and the
inability of bacteria to form a resistance to it. PURE is headquartered
in El Cajon, California (San Diego metropolitan area). Additional
information on PURE is available at www.purebio.com.

Forward-looking Statements
Any statements contained in
this press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Forward-looking statements
inherently involve risks and uncertainties that could cause our actual
results to differ materially from the forward-looking statements.
Factors that could cause or contribute to such differences include, but
are not limited to, the Company’s failure to implement or otherwise
achieve the benefits of its proposed business initiatives and plans;
acceptance of the Company’s current and future products and services in
the marketplace, including acceptance of the Company’s PURE Hard Surface
disinfectant by SUBWAY® franchisees; the ability to convert successful
evaluations into customer orders; the ability of the Company to develop
effective new products and receive required regulatory approvals for
such products, including the regulatory approvals required to use its
SDC-based technology as a direct food contact processing aid in raw
poultry, produce and raw meat processing; competitive factors;
dependence upon third-party vendors, including to manufacture its
products; and other risks detailed in the Company’s periodic report
filings with the Securities and Exchange Commission (the SEC), including
its Form 10-K for the fiscal year ended July 31, 2015 and filed with the
SEC on October 28, 2015. You should not place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or
changes after the date of this release.


PURE Bioscience, Inc.
Hank Lambert, CEO
619-596-8600 ext.103
+ MacInnis, Inc.
Terri MacInnis, VP of IR
Investment Group
Tom Hemingway, 714-978-4425